Business Segments Kobayashi Pharmaceutical Co., Ltd. Deutsche Boerse AG
Stocks
KOY
JP3301100008
Personal Products
|
Real-time Estimate
Tradegate
05:12:20 2026-09-16 EDT
|
5-day change | 1st Jan Change | ||
| 32.50 EUR | +2.85% |
|
+1.29% | +9.79% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Beauty Care Products | ||||||||||
Domestic Business (Incl. Mail Order Business) | - | - | 137B | 124B | 123B | |||||
Total Assets | - | - | 102B | 113B | 118B | |||||
CAPEX | - | - | - | -16.94B | -13.47B | |||||
D&A | - | - | 2.78B | 3.51B | 3.9B | |||||
Operating Income | - | - | 22.03B | 23.22B | 13.96B | |||||
| - | - | - | - | 4.86B | ||||||
Apparel | ||||||||||
International Business | 31.14B | 41.55B | 44.13B | 46.84B | 48.42B | |||||
Total Assets | 38.83B | 49.57B | 65.2B | 75.87B | 85.78B | |||||
Interest Expense | - | - | - | - | - | |||||
CAPEX | -1.15B | -3.08B | - | -7.31B | -6.4B | |||||
EBT | - | - | - | - | - | |||||
D&A | 2.18B | 2.59B | 3.05B | 4.26B | 3.17B | |||||
Operating Income | 911M | 3.23B | 3.22B | 1.27B | 810M | |||||
| - | - | - | - | 1.42B | ||||||
Road Transportation of Freight | ||||||||||
Others | 6.76B | 6.84B | 7.06B | 6.51B | 6.58B | |||||
Total Assets | 5.67B | 5.94B | 5.68B | 5.45B | 5.54B | |||||
Interest Expense | - | - | - | - | - | |||||
CAPEX | -86M | -197M | - | -261M | -298M | |||||
EBT | - | - | - | - | - | |||||
D&A | 220M | 200M | 200M | 223M | 252M | |||||
Operating Income | 820M | 528M | 493M | 264M | 215M | |||||
| - | - | - | - | 5.9B | ||||||
Unallocated Adjustment | -13.6B | -14.82B | -14.28B | -11.68B | -12.17B | |||||
Total Assets | 126B | 114B | 94.42B | 70.7B | 66.25B | |||||
Interest Expense | - | - | - | - | - | |||||
CAPEX | -429M | -1.11B | - | -347M | -556M | |||||
EBT | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | 1M | 52M | 38M | 105M | -66M | |||||
Pharmaceutical Products | ||||||||||
Domestic Business | 122B | 124B | - | - | - | |||||
Total Assets | 80.71B | 84.92B | - | - | - | |||||
Interest Expense | - | - | - | - | - | |||||
CAPEX | -3.57B | -11.36B | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | 2.36B | 2.48B | - | - | - | |||||
Operating Income | 23.94B | 22.43B | - | - | - | |||||
Vitamins and Nutritional Supplements | ||||||||||
Mail Order Business | 8.99B | 8.44B | - | - | - | |||||
Total Assets | 1.6B | 1.55B | - | - | - | |||||
CAPEX | -48M | -44M | - | - | - | |||||
EBT | - | - | - | - | - | |||||
D&A | 47M | 57M | - | - | - | |||||
Operating Income | 397M | 420M | - | - | - |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Japan | 126B | 127B | 131B | 120B | 119B | |||||
Total Assets | 18.25B | 28.21B | 34.5B | 48.19B | 43.17B | |||||
| - | - | - | - | 23.81B | ||||||
USA | 13.01B | 16.47B | 17.06B | 21.25B | 23.81B | |||||
Total Assets | - | - | - | 8.02B | 11.7B | |||||
China | 10.07B | 12.48B | 13.65B | - | 9.61B | |||||
Total Assets | 2.72B | 4.36B | 9.17B | 10.96B | 10.53B | |||||
| - | - | - | - | 9.3B | ||||||
Southeast Asia | 4.21B | 7.49B | 7.93B | - | 9.3B | |||||
| - | - | - | - | 4.26B | ||||||
Others | 2.46B | 3.22B | 3.65B | 23.93B | 4.26B | |||||
Total Assets | - | - | - | 277M | 1.96B | |||||
Abroad | - | - | - | - | - | |||||
Total Assets | 1.56B | 2.21B | 4B | - | - | |||||
| - | - | - | - | 9.61B | ||||||
| - | - | - | - | 119B |
Select your edition
All financial news and data tailored to specific country editions
